Cancer Immunotherapy, Part 2: Efficacy, Safety, and Other Clinical Considerations.

Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med (2010) 29.75

National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant (2005) 19.83

Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science (2002) 19.77

Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol (2008) 10.13

Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol (1996) 9.68

Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res (2011) 9.03

Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol (2012) 7.39

Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J Natl Cancer Inst (1994) 7.20

Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA (1994) 6.36

Gene transfer into humans--immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. N Engl J Med (1990) 5.27

gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med (2011) 5.15

Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials. JAMA (2009) 4.08

Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev (2005) 3.88

Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol (2003) 3.38

Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom? Blood (2007) 3.18

A retrospective analysis of therapy for acute graft-versus-host disease: initial treatment. Blood (1990) 2.32

Correlation between NIH composite skin score, patient-reported skin score, and outcome: results from the Chronic GVHD Consortium. Blood (2012) 2.19

A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS. Blood (2009) 1.90

Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): an intention-to-treat analysis of the EORTC/GIMEMAAML-10 trial. Blood (2003) 1.84

High-dose interleukin-2 for the treatment of metastatic renal cell carcinoma : a retrospective analysis of response and survival in patients treated in the surgery branch at the National Cancer Institute between 1986 and 2006. Cancer (2008) 1.74

Clinical trial results of the HER-2/neu (E75) vaccine to prevent breast cancer recurrence in high-risk patients: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02. Cancer (2011) 1.38

Adjuvant interferon therapy for melanoma: high-dose, low-dose, no dose, which dose? J Clin Oncol (2003) 1.28

Granulocyte-macrophage colony-stimulating factor (GM-CSF)-secreting cellular immunotherapy in combination with autologous stem cell transplantation (ASCT) as postremission therapy for acute myeloid leukemia (AML). Blood (2009) 1.18

Nonmalignant late effects and compromised functional status in survivors of hematopoietic cell transplantation. J Clin Oncol (2011) 1.17

Interleukin 2 in cancer therapy. Curr Med Chem (2010) 1.09

Toxicities of chimeric antigen receptor T cells: recognition and management. Blood (2016) 1.07

Cancer immunotherapy: harnessing the immune system to battle cancer. J Clin Invest (2015) 1.04

Cancer and the Immune System: Basic Concepts and Targets for Intervention. Semin Oncol (2015) 1.03

Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper. Ann Oncol (2015) 0.98

Cancer immunotherapy in clinical practice -- the past, present, and future. Chin J Cancer (2014) 0.98

Current Challenges in Cancer Treatment. Clin Ther (2016) 0.95

Treatment of metastatic melanoma with autologous, hapten-modified melanoma vaccine: regression of pulmonary metastases. Int J Cancer (2001) 0.94

Cancer immunotherapies, their safety and toxicity. Expert Opin Drug Saf (2013) 0.91

Phase II trials of recombinant leukocyte A interferon in disseminated malignant melanoma: results in 96 patients. Cancer Treat Rep (1986) 0.90

Efficacy and safety of ipilimumab in elderly patients with pretreated advanced melanoma treated at Italian centres through the expanded access programme. J Exp Clin Cancer Res (2014) 0.89

The development of immunotherapy in older adults: New treatments, new toxicities? J Geriatr Oncol (2016) 0.86

Management of toxicities associated with high-dose interleukin-2 and biochemotherapy. Anticancer Drugs (2013) 0.86

New approaches for cancer immunotherapy. Tumour Biol (2015) 0.85

Immunotherapy Approaches in Cancer Treatment. Curr Pharm Biotechnol (2015) 0.85

Recent advances in the field of anti-cancer immunotherapy. BBA Clin (2015) 0.85

Cancer immunology for the clinician. Clin Adv Hematol Oncol (2015) 0.84

Cancer immunoprevention--the next frontier. Cancer Prev Res (Phila) (2014) 0.82

The safety of therapeutic monoclonal antibodies: implications for cardiovascular disease and targeting the PCSK9 pathway. Atherosclerosis (2013) 0.81

Advances in Therapeutic Cancer Vaccines. Adv Immunol (2016) 0.79

A multidisciplinary approach to toxicity management of modern immune checkpoint inhibitors in cancer therapy. Melanoma Res (2016) 0.76

Ruxolitinib in steroid refractory graft-vs.-host disease: a case report. J Hematol Oncol (2016) 0.75

Social media and health care professionals: benefits, risks, and best practices. P T (2014) 2.08

The antibiotic resistance crisis: part 1: causes and threats. P T (2015) 1.90

Mobile devices and apps for health care professionals: uses and benefits. P T (2014) 1.63

The drug shortage crisis in the United States: causes, impact, and management strategies. P T (2011) 1.57

Direct-to-Consumer Pharmaceutical Advertising: Therapeutic or Toxic? P T (2011) 1.56

Medical Applications for 3D Printing: Current and Projected Uses. P T (2014) 1.36

Current Issues Regarding Complementary and Alternative Medicine (CAM) in the United States: Part 1: The Widespread Use of CAM and the Need for Better-Informed Health Care Professionals to Provide Patient Counseling. P T (2010) 1.07

Off-label drug information: regulation, distribution, evaluation, and related controversies. P T (2009) 1.05

Biosimilars: part 2: potential concerns and challenges for p&t committees. P T (2013) 0.99

Pharmacogenomics in clinical practice: reality and expectations. P T (2011) 0.94

An Interview Series with Members of the ASHP Expert Panel on Formulary Management: Part 2: J. Russell May, PharmD. P T (2009) 0.89

The antibiotic resistance crisis: part 2: management strategies and new agents. P T (2015) 0.89

The nanomedicine revolution: part 2: current and future clinical applications. P T (2012) 0.85

The nanomedicine revolution: part 1: emerging concepts. P T (2012) 0.83

Role of pharmacogenomic biomarkers in predicting and improving drug response: part 1: the clinical significance of pharmacogenetic variants. P T (2013) 0.82

Current Issues Regarding Complementary and Alternative Medicine (CAM) in the United States: Part 2: Regulatory and Safety Concerns and Proposed Governmental Policy Changes with Respect to Dietary Supplements. P T (2010) 0.80

Evaluation of Biosimilars for Formulary Inclusion: Factors for Consideration by P&T Committees. P T (2015) 0.78

The nanomedicine revolution: part 3: regulatory and safety challenges. P T (2012) 0.77

Epilepsy management: newer agents, unmet needs, and future treatment strategies. P T (2014) 0.76

The role of pharmacogenomic biomarkers in predicting and improving drug response: part 2: challenges impeding clinical implementation. P T (2013) 0.75

An Interview Series with Members of the ASHP Expert Panel on Formulary Management: Part 1: Linda S. Tyler, PharmD. P T (2009) 0.75

An Interview Series with Members of the ASHP Expert Panel on Formulary Management: Part 3: Sabrina W. Cole, PharmD. P T (2010) 0.75

Immunization in the United States: Recommendations, Barriers, and Measures to Improve Compliance: Part 1: Childhood Vaccinations. P T (2016) 0.75

Current Issues Regarding Complementary and Alternative Medicine (CAM) in the United States: Part 3: Policies and Practices Regarding Dietary Supplements In Health Care Facilities. P T (2010) 0.75

Immunization in the United States: Recommendations, Barriers, and Measures to Improve Compliance: Part 2: Adult Vaccinations. P T (2016) 0.75

Cancer Immunotherapy, Part 1: Current Strategies and Agents. P T (2017) 0.75

Progress in Nanomedicine: Approved and Investigational Nanodrugs. P T (2017) 0.75

Cancer Immunotherapy, Part 3: Challenges and Future Trends. P T (2017) 0.75